Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
71°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Glycomimetics Inc
(NQ:
GLYC
)
0.1522
-0.0136 (-8.20%)
Streaming Delayed Price
Updated: 3:35 PM EDT, Oct 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Glycomimetics Inc
< Previous
1
2
3
4
5
6
Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 24, 2024
Via
Benzinga
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
January 04, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Why Trinity Place Holdings Shares Are Trading Higher By 80%; Here Are 20 Stocks Moving Premarket
January 03, 2024
Shares of Trinity Place Holdings Inc. (NYSE: TPHS) rose sharply in pre-market trading. The company reported in 8K Filing, mortgage lender agreed to extend the mortgage loan forbearance period to Jan....
Via
Benzinga
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
January 03, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Earnings Outlook For GlycoMimetics
November 02, 2023
Via
Benzinga
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
December 10, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
November 09, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
November 03, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
October 20, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics: Q1 Earnings Insights
May 03, 2023
Via
Benzinga
Earnings Preview For GlycoMimetics
March 28, 2023
Via
Benzinga
Earnings Scheduled For November 3, 2023
November 03, 2023
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.
Via
Benzinga
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
September 06, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
August 02, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
July 19, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Announces Its Addition to the Russell Microcap® Index
June 26, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
June 15, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference
May 31, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics: A Breakthrough In Hematopoietic Stem Cell Transplantation
May 09, 2023
Blood cancers such as AML, MM, and MDS affect a terrible toll on patients and their loved ones. Glycomimetics may be such a company that can offer patients suffering from various blood cancers hope...
Via
Talk Markets
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023
May 03, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023
April 26, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
March 29, 2023
Via
Benzinga
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022
March 29, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 29, 2023
Gainers LogicMark, Inc. (NASDAQ: LGMK) shares jumped 76.1% to $0.2466 after the company announced financial results for the year ended 2022. The company reported FY22 revenue of $11.9 million.
Via
Benzinga
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023
March 16, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
March 13, 2023
Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of...
Via
Benzinga
GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference
March 01, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 21, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.